Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma-Reference-Cited by-同舟云学术

Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

Published:1992-02 Issue:2 Volume:36 Page:183-186
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Modlgliani E.,Cohen R.,Joannldis S.,Slame-Mourot C.,Guliana J. M.,Charpentier G.,Cassuto D.,Bentala Pessayre M.,Tabarin A.,Roger P.,Caron P.,Gulllausseau P. J.,Lalau J. D.,Tournlafre J.,Bayard F.,Aulévre P.,James-Deldier A.,Catmettest C.

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.1992.tb00955.x/fullpdf

Reference14 articles.

1. MOLECULAR WEIGHT FORMS OF IMMUNOREACTIVE CALCITONIN IN A PATIENT WITH MEDULLARY CARCINOMA OF THE THYROID: DYNAMIC STUDIES WITH CALCIUM, PENTAGASTRIN AND SOMATOSTATIN

2. G. Sacco, F. Muratori, U Verga, and A Libroia . (1990 ) The use of sandostatin in the treatment of recurrent medullary thyroid carcinoma.Medullary Thyroid Carcinoma, 1st European Congress, Paris France. Abstract 45, p.104 .

3. SOMATOSTATIN INHIBITS THE PENTAGASTRIN-INDUCED RELEASE OF SERUM CALCITONIN IN MEDULLARY CARCINOMA OF THE THYROID

4. Diagnosis of Medullary Carcinoma of the Thyroid (MCT) by Calcitonin Assay Using Monoclonal Antibodies: Criteria for the Pentagastrin Stimulation Test in Hereditary MCT

5. Effects of Short-Term Subcutaneous Administration of SMS 201-995 on Calcitonin Plasma Levels in Patients Suffering from Medullary Thyroid Carcinoma

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radionuclide Therapy of Thyroid Tumors;Nuclear Oncology;2022

2. Radionuclide Therapy of Thyroid Tumors;Nuclear Oncology;2022

3. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion;Molecular and Cellular Endocrinology;2021-01

4. Medullary Thyroid Cancer;The Thyroid and Its Diseases;2019

5. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study;Endocrine;2018-03-23